Optic neuritis

Eye

Volumn 25, Issue 7, 2011, Pages 833-842

  Pau, D ^a   Al Zubidi, N ^a   Yalamanchili, S ^a   Plant, G T ^b,c,d   Lee, A G ^a,e,f,g  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

demyelinating optic neuritis; multiple sclerosis; neuromyelitis optica; optic neuritis; visual loss

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB;

ACUTE PANCREATITIS; AVASCULAR NECROSIS; CEREBROSPINAL FLUID ANALYSIS; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DEPRESSION; DISEASE ASSOCIATION; EYE PAIN; FLUSHING; GENETICS; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUMBAR PUNCTURE; MEDICAL LITERATURE; MEDLINE; MOOD CHANGE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH DISCOMFORT; VISUAL IMPAIRMENT;

EID: 79960439352     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.81     Document Type: Review

References (81)

1. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75: 208-216.
2. Söderström M, Link H, Sun JB, Fredrikson S, Wang ZY, Huang WX. Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1994; 57: 544-551. (Pubitemid 24151244)
3. Prineas J. Pathology of multiple sclerosis. In: Cook S (ed.). Handbook of Multiple Sclerosis. Marcel Dekker: Basel (Switzerland), 2001, pp 289-324.
4. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57. (Pubitemid 29058945)
5. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-171. (Pubitemid 36143722)
6. Brück W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003; 24; S265-S267. (Pubitemid 37493197)
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285. (Pubitemid 28065253)
8. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI et al. Quantifying axonal loss after optic neuritis with optic coherence tomography. Ann Neurol 2006; 59: 963-969. (Pubitemid 43830928)
9. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005; 58: 383-391. (Pubitemid 41266624)
10. Shams PN, Plant GT. Optic neuritis: a review. Int MS J 2009; 16: 82-89.
11. Kurtzke JF. Optic neuritis or multiple sclerosis. Arch Neurol 1985; 42: 704-710. (Pubitemid 15062832)
12. Rodriguez M, Siva A, Cross SA, OBrien PC, Kurland LT. Optic neuritis: a population based study in Olmsted County, Minnesota. Neurology 1995; 45: 244-250.
13. Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol 1972; 87: 135.
14. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55: 186-192. (Pubitemid 28110061)
15. Bhigjee AI, Moodley K, Ramkissoon K. Multiple sclerosis in KwaZulu Natal, South Africa: an epidemiological and clinical study. Mult Scler 2007; 13: 1095-1099. (Pubitemid 351541412)
16. Mbonda E, Larnaout A, Maertens A, Appel B, Lowenthal A, Mbede J et al. Multiple sclerosis in a black Cameronian woman. Acta Neurol Belg 1990; 90: 218-222.
17. Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43: 127-132. (Pubitemid 29225336)
18. El-Salem K, Al-Shimmery E, Horany K, Al-Refai A, Al-Hayk K, Khader Y. Multiple sclerosis in Jordan: a clinical and epidemiological study. J Neurol 2006; 253: 1210-1216. (Pubitemid 44511480)
19. Al-Araji A, Mohammed AI. Multiple sclerosis in Iraq: does it have the same features encountered in western countries? J Neurol Sci 2005; 15: 67-71. (Pubitemid 40910345)
20. Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008; 15: 1273-1278.
21. Kurtzke JF. Multiple sclerosis among immigrants. Br Med J 1976; 1: 1527-1528.
22. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 565-568. (Pubitemid 27489217)
23. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. J Neurol Sci 2009; 286: 58-61.
24. Cabre P, Signate A, Olindo S, Merle H, Caparros-Lefebvre D, Béra O et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005; 128: 2899-2910. (Pubitemid 41746643)
25. Zhang X, Wang W, Wei W, Wang Q, Wei Y, Kermode AG. Etiological profile of presumptive optic neuritis in China. J Clin Neurosci 2008; 15: 1346-1349.
26. Lim SA, Goh KY, Tow S, Fu E, Wong TY, Seah A et al. The pattern of ON as seen in Singapore differs from that reported in Caucasian studies and from the seminal Optic Neuritis Treatment Trial. Singapore Med J 2008; 49: 667-671.
27. Jin Y, de Pedro-Cuesta J, Söderström M, Stawiarz L, Link H. Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000; 181: 56-64.
28. Balashov KE, Pal G, Rosenberg ML. Optic neuritis incidence is increased in spring months in patients with asymptomatic demyelinating lesions. Mult Scler 2010; 16: 252-254.
29. Allen L, Brankin B. Pathogenesis of multiple sclerosisFthe immune diathesis and the role of viruses. J Neuropathol Exp Neurol 1993; 52: 95-105. (Pubitemid 23069765)
30. Power C, Antony JM, Ellestad KK, Deslauriers A, Bhat R, Noorbakhsh F. The human microbiome in multiple sclerosis: pathogenic or protective constituents? Can J Neurol Sci 2010; 37: S24-S33.
31. Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354: 1273-1280.
32. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18: 174-180. (Pubitemid 39093274)
33. Brady KM, Brar AS, Lee AG, Coats DK, Paysse EA, Steinkuller PG. Optic neuritis in children: clinical features and visual outcome. J Amer Acad Pediatr Ophthlamol Strab 1999; 3: 98-103.
34. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000; 37: 254-259.
35. Lucchinetti CF, Kiers L, ODuffy A, Gomez MR, Cross S, Leavitt JA et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49: 1413-1418. (Pubitemid 27495652)
36. Celesia GG, Kaufman DI, Brigell M, Toleikis S, Kokinakis D, Lorance R et al. Optic neuritis: a prospective study. Neurology 1990; 40: 919-923. (Pubitemid 20201816)
37. Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997; 115: 1545-1552.
38. Kaur P, Bennett JL. Optic neuritis and the neuroophthalmology of multiple sclerosis. Int Rev Neurobiol 2007; 79: 633-663.
39. Schneck ME, Haegerstrom-Portnoy G. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997; 38: 2278-2289. (Pubitemid 27446945)
40. Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW et al. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol 2010; 128: 330-337.
41. Cox TA, Thompson HS, Corbett JJ. Relative afferent pupillary defects in optic neuritis. Am J Ophthalmol 1981; 92: 685-690. (Pubitemid 11031742)
42. Kawasaki A. Physiology, assessment, and disorders of the pupil. Curr Opin Ophthalmol 1999; 10: 394-400.
43. Warner JE, Lessell S, Rizzo III JF, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Arch Ophthalmol 1997; 115: 1408-1410.
44. Goldstein JE, Cogan DG. Exercise and the optic neuropathy of multiple sclerosis. Arch Ophthalmol 1964; 72: 168-170.
45. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137: 77-83. (Pubitemid 38045190)
46. Mojon DS, Rö sler KM, Oetliker H. A bedside test to determine motion stereopsis using the Pulfrich phenomenon. Ophthalmology 1998; 105: 1337-1344. (Pubitemid 28470909)
47. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI, Optic Neuritis Study Group. Brain MRI in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol 1993; 8: 841-846. (Pubitemid 23229311)
48. Optic Neuritis Study Group. The five-year risk of multiple sclerosis after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49: 1404-1413.
49. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-732.
50. Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrastenhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002; 125: 812-822. (Pubitemid 34279776)
51. Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996; 46: 368-372. (Pubitemid 26081315)
52. Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51: 885-887. (Pubitemid 28449282)
53. Optic Neuritis Treatment Group. Visual function 15 years after optic neuritis. Ophthalmology 2008; 115: 1079-1082.
54. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999; 18: 53-63. (Pubitemid 29095753)
55. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479-1484. (Pubitemid 29190544)
56. Chrousos GA, Kattah JC, Beck RW, Cleary PA, The Optic Neuritis Study Group. Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993; 269: 2110-2112. (Pubitemid 23112630)
57. McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ 2001; 164: 205-206. (Pubitemid 32157743)
58. Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Mrup A et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810. (Pubitemid 40316316)
59. Noseworthy JH, OBrien PC, Petterson TM, Weis J, Stevens L, Peterson WK et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522. (Pubitemid 32532263)
60. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of patients. Neurology 2004; 63: 1081-1083. (Pubitemid 39287920)
61. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-1769. (Pubitemid 23355549)
62. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet 2002; 360: 1953-1962. (Pubitemid 35472140)
63. Hickman SJ, Jay WM, Ko M, Chaudhry F, Plant GT. Optic neuritis: an update typical and atypical optic neuritis. Neuroophthalmology 2008; 32: 237-248.
64. Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011; 82: 176-179.
65. Swanton J, Fernando K, Dalton C, Miszkiel K, Altmann D, Plant G et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010; 16: 156-165.
66. Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol 2001; 21: 292-295. (Pubitemid 34027532)
67. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582. (Pubitemid 32488815)
68. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397. (Pubitemid 47189673)
69. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 2003; 121: 944-949.
70. Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011; 82: 176-179.
71. Wingerchuk DM, Hogancamp WF, OBrien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devics syndrome). Neurology 1999; 53: 1107-1114. (Pubitemid 29442132)
72. Wingerchuki DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853. (Pubitemid 36297372)
73. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489. (Pubitemid 43958540)
74. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
75. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM et al. A role for humoral mechanisms in the pathogenesis of Devics neuromyeltis optica. Brain 2002; 125: 1450-1461. (Pubitemid 34755161)
76. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010; 81: 109-111.
77. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968. (Pubitemid 44036298)
78. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM et al. Aquaporin-4 autoimmune syndrome and antiaquaporin-antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009; 15: 834-847.
79. Weinshenker BG, OBrien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
80. Cree B, Lamb S, Chin A, Bonovich D, Islar J,Waubant E et al. Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optical (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 2004; 62: A492.
81. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F et al. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. Neurol 2007; 254: 1233-1237. (Pubitemid 350112363)